Relay Therapeutics, Inc.

NASDAQ:RLAY

Biotechnology

Healthcare
$15.91 +2.63%

+$0.41 today

Market cap
$3.52B
Beta
1.75
P/E (TTM)
-10.5
EPS (TTM)
-$1.52
52W Low $3.03High $17.47

Volume 1.88M

Average 3.70M

Returns on capital

Relay Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-48.8%

avg -16.8%

ROIC

-50.5%

avg -31.0%

ROA

-44.5%

avg -27.6%

Analysis

ROA is currently the strongest return metric at -44.5% versus its period average of -27.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Sanjiv K. Patel MBBS

Chief Executive Officer, President & DirectorUSD 1.13M52——

Donald A. Bergstrom

President of Research & DevelopmentUSD 817.66K54396.88K0.23%

Thomas Catinazzo

Chief Financial OfficerUSD 694.11K50103.67K0.06%

Peter Rahmer

Chief Corporate Development OfficerUSD 670.67K44222.90K0.13%

Mark Murcko

Founder & Independent DirectorUSD 65.92K6632.95K0.02%

Soo-Yeun Lim

Senior Vice President & General Counsel————

David Elliot Shaw

Founder—75——

Matthew Jacobson

Founder————

Dorothee Kern

Founder————

Jim Watters

Chief Scientific Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Oct 28, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

37

$127.18M

Net Transaction Value

−$127.18M

Net selling

Most Active

Catinazzo Thomas

16 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Oct 28, 26

Bergstrom Donald A

Direct

Sell$41.9K
Oct 28, 26

Catinazzo Thomas

Direct

Sell$27.4K
Oct 28, 26

Rahmer Peter

Direct

Sell$14K
Oct 7, 26

Patel Sanjiv

Direct

Sell$872.4K
Oct 6, 26

Catinazzo Thomas

Direct

Sell$325.4K
Oct 6, 26

Catinazzo Thomas

Direct

Sell$4K
Sep 8, 26

Bergstrom Donald A

Direct

Sell$161.8K
Sep 8, 26

Catinazzo Thomas

Direct

Sell$335.6K
Sep 8, 26

Patel Sanjiv

Direct

Sell$912.9K
Aug 26, 26

Rahmer Peter

Direct

Sell$90.3K

1–10 of 37

Summary

Insiders reported 0 buys worth $0.00 and 37 sells worth $127.18M over the last 12 months. That adds up to net selling of $127.18M. Catinazzo Thomas was the most active insider with 16 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A3 analysts
RevenueN/AN/A+123.2%
+97.7% (5yr)4 analysts
Net IncomeN/AN/AN/A
N/A4 analysts
EBITN/AN/AN/A
N/A4 analysts

Analysis

Recent growth has been strongest in Revenue at +123.2% over three years. Forward estimates point to Revenue at +97.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Relay Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about RLAY's management, answered from reported figures.

Who manages RLAY?

Relay Therapeutics, Inc. (RLAY) lists 10 active executives. The top listed executive is Soo-Yeun Lim, Senior Vice President & General Counsel.

Are RLAY insiders buying or selling?

Recent insider activity shows net selling of $87.37M.